Why the study?
Does preoperative continuous infusion of cis-platinum and Adriamycin improve resectability and survival in patients with initially unresectable hepatoblastoma?
Does preoperative continuous infusion of cis-platinum and Adriamycin improve resectability and survival in patients with initially unresectable hepatoblastoma?
Preoperative continuous infusion of cis-platinum and Adriamycin may successfully convert initially unresectable hepatoblastoma to resectable disease.
Answers are grounded in this paper and cite their sources.
May support resectability conversion in unresectable hepatoblastoma; hypothesis-generating and should not yet change practice.
Hepatoblastoma deemed surgically unresectable at presentation is fatal unless conversion to resectability is attained. We report a series of six consecutive patients, ranging in age from newborn to 5.75 years with hepatoblastoma unresectable at presentation, either because of size of tumor or its anatomical boundaries, or because of metastatic disease. All were treated with preoperative continuous infusions of cis-platinum and Adriamycin. All achieved resectability, and there was only one operative death. The five surviving patients are alive and free of disease off therapy. Potential benefit may accrue from preoperative chemotherapy in most cases of hepatoblastoma.
No takes yet. Share an insight, caveat, or question.
Langevin et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: